ArticleScientific reports2025
BGATT-GR: accurate identification of glucocorticoid receptor antagonists based on data augmentation combined with BiGRU-attention.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- MIF-MAPMS: Enhancing identification of myelin autoantigenic peptides in multiple sclerosis through multimodal information fusion.Protein science : a publication of the Protein Society · 2026Article
- NToxSEM: Enhancing prediction of neurotoxic peptides and neurotoxins using a stacked ensemble-based multimodal framework.Protein science : a publication of the Protein Society · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The glucocorticoid receptor (GR) is a critical nuclear receptor that regulates a broad spectrum of physiological functions, including stress adaptation, immune response, and metabolism. Given the association between aberrant GR signaling and various pathological conditions, this pathway represents a promising therapeutic target. Several GR antagonists have been developed to block glucocorticoid binding to the receptor, showing therapeutic potential in disorders characterized by heightened or dysregulated glucocorticoid signaling. Therefore, this study proposes an innovative deep learning-based hybrid framework (termed BGATT-GR) that leverages a data augmentation method, a bidirectional gated recurrent unit (BiGRU), and a self-attention mechanism (ATT) to attain more accurate identification of GR antagonists. In BGATT-GR, we first employed AP2D, CDKExt, KR, Morgan, and RDKIT to extract molecular descriptors of GR antagonists and combined these molecular descriptors to generate multi-view features. Second, we adopted a data augmentation method that combined both random under-sampling (RUS) and the synthetic minority over-sampling technique (SMOTE) to address the issue of class imbalance. Third, the BGATT architecture was constructed to enhance the utility of the multi-view features by generating informative feature embeddings. Finally, we applied principal component analysis (PCA) to reduce the dimensionality of these feature embeddings and fed the processed feature vectors into the final classifier. Extensive experimental results showed that BGATT-GR provided more stable performance in both cross-validation and independent tests. Furthermore, the independent test results revealed that BGATT-GR attained superior predictive performance compared with several conventional ML models, with a balanced accuracy of 0.957, an MCC of 0.853, and an AUPR of 0.962. In summary, our experimental results provide strong evidence to suggest that BGATT-GR is highly accurate and effective for identifying GR antagonists.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.